NASDAQ:ADMP - Adamis Pharmaceuticals Stock Price, Forecast & News

Adamis Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMP."

Adamis Pharmaceuticals Corp (NASDAQ:ADMP) issued its quarterly earnings results on Tuesday, November, 12th. The specialty pharmaceutical company reported ($0.12) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.06) by $0.06. The specialty pharmaceutical company earned $5.90 million during the quarter, compared to the consensus estimate of $6.55 million. Adamis Pharmaceuticals had a negative net margin of 175.77% and a negative return on equity of 90.00%. View Adamis Pharmaceuticals' Earnings History.

Adamis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Friday, March 20th 2020. View Earnings Estimates for Adamis Pharmaceuticals.

4 brokers have issued 1 year price objectives for Adamis Pharmaceuticals' stock. Their forecasts range from $1.10 to $6.00. On average, they anticipate Adamis Pharmaceuticals' stock price to reach $3.70 in the next twelve months. This suggests a possible upside of 408.6% from the stock's current price. View Analyst Price Targets for Adamis Pharmaceuticals.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adamis Pharmaceuticals in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Adamis Pharmaceuticals.

Media stories about ADMP stock have trended somewhat positive recently, according to InfoTrie. InfoTrie rates the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Adamis Pharmaceuticals earned a media sentiment score of 1.8 on InfoTrie's scale. They also gave news headlines about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Adamis Pharmaceuticals.

Some companies that are related to Adamis Pharmaceuticals include Strongbridge Biopharma (SBBP), Neptune Wellness Solutions (NEPT), NuCana (NCNA), Avenue Therapeutics (ATXI), Spero Therapeutics (SPRO), Akorn (AKRX), Harrow Health (HROW), Five Prime Therapeutics (FPRX), Abeona Therapeutics (ABEO), Evelo Biosciences (EVLO), Scpharmaceuticals (SCPH), Obseva (OBSV), vTv Therapeutics (VTVT), Selecta Biosciences (SELB) and Adamas Pharmaceuticals (ADMS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Adamis Pharmaceuticals investors own include Synergy Pharmaceuticals (SGYP), Trevena (TRVN), Verastem (VSTM), Sorrento Therapeutics (SRNE), Agile Therapeutics (AGRX), Novavax (NVAX), Amarin (AMRN), Aurinia Pharmaceuticals (AUPH), Corbus Pharmaceuticals (CRBP) and Exelixis (EXEL).

Shares of ADMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ADMP stock can currently be purchased for approximately $0.73.

Adamis Pharmaceuticals has a market capitalization of $44.84 million and generates $15.09 million in revenue each year. The specialty pharmaceutical company earns $-39,010,000.00 in net income (profit) each year or ($1.00) on an earnings per share basis. Adamis Pharmaceuticals employs 152 workers across the globe.View Additional Information About Adamis Pharmaceuticals.

The official website for Adamis Pharmaceuticals is http://www.adamispharmaceuticals.com/.

Adamis Pharmaceuticals' mailing address is 11682 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. The specialty pharmaceutical company can be reached via phone at 858-997-2400 or via email at [email protected]